TD Asset Management Inc Has $7.67 Million Position in Axsome Therapeutics, Inc. $AXSM

TD Asset Management Inc lessened its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 5.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 41,972 shares of the company’s stock after selling 2,220 shares during the quarter. TD Asset Management Inc’s holdings in Axsome Therapeutics were worth $7,666,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of AXSM. Optiver Holding B.V. lifted its position in Axsome Therapeutics by 82.3% during the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock worth $35,000 after acquiring an additional 130 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in Axsome Therapeutics during the 3rd quarter worth approximately $38,000. Advisory Services Network LLC acquired a new stake in Axsome Therapeutics during the 3rd quarter worth approximately $40,000. GAMMA Investing LLC boosted its stake in Axsome Therapeutics by 65.4% in the 4th quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock valued at $49,000 after purchasing an additional 106 shares during the period. Finally, Farther Finance Advisors LLC grew its holdings in Axsome Therapeutics by 602.6% in the 4th quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock valued at $50,000 after buying an additional 235 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AXSM. Piper Sandler reissued an “overweight” rating and issued a $258.00 target price on shares of Axsome Therapeutics in a research report on Monday, May 4th. Jefferies Financial Group lifted their price objective on shares of Axsome Therapeutics from $245.00 to $275.00 and gave the stock a “buy” rating in a research note on Monday, May 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $272.00 price objective on shares of Axsome Therapeutics in a report on Monday, May 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Monday, April 20th. Finally, Truist Financial upgraded shares of Axsome Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $251.26.

Insider Activity at Axsome Therapeutics

In related news, insider Ari Maizel sold 7,500 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $182.42, for a total value of $1,368,150.00. Following the transaction, the insider directly owned 7,500 shares of the company’s stock, valued at $1,368,150. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Mark L. Jacobson sold 4,517 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $227.94, for a total value of $1,029,604.98. Following the completion of the sale, the chief operating officer owned 4,517 shares in the company, valued at $1,029,604.98. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 112,457 shares of company stock valued at $26,364,328 in the last quarter. Insiders own 20.60% of the company’s stock.

Axsome Therapeutics Price Performance

Shares of AXSM opened at $245.64 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 1.39 and a debt-to-equity ratio of 2.27. The stock has a market cap of $12.64 billion, a PE ratio of -65.86 and a beta of 0.61. Axsome Therapeutics, Inc. has a 12-month low of $96.09 and a 12-month high of $246.41. The business has a 50-day simple moving average of $205.86 and a two-hundred day simple moving average of $179.97.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). The firm had revenue of $191.20 million for the quarter, compared to analyst estimates of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. Axsome Therapeutics’s revenue for the quarter was up 57.4% compared to the same quarter last year. Analysts anticipate that Axsome Therapeutics, Inc. will post -2.24 earnings per share for the current fiscal year.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.